Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Vaccine shows promise in glioblastoma

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 15, 2023 9:23am

170 Views

Post# 35497753

RE:Vaccine shows promise in glioblastoma

Reovirus infection is associated with selective down-regulation of cellular IAPs, including c-IAP1, XIAP, and survivin, effects that are blocked by Bcl-2 expression, establishing the dependence of IAP down-regulation on mitochondrial events.

https://pubmed.ncbi.nlm.nih.gov/12388702/

Reoviruses induce apoptosis in multiple cell lines in vitro, and was found to increase survivin expession post reovirus injection.

https://journals.asm.org/doi/10.1128/JVI.77.16.8934-8947.2003

<< Previous

Bullboard Posts

Next >>

Twelve Labs partners with AWS to revolutionize video search with AI